TG Therapeutics Inc., of New York, reported results from its ongoing phase II trial testing ublituximab (TG-1101), a glycoengineered anti-CD20 monoclonal antibody, in patients with the relapsing forms of multiple sclerosis (RMS) at the 3rd Annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2018 in San Diego.